ArticleOncotarget2014
Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Meta-analysis of the Relationship between Type 2 Diabetes Mellitus and Renal Cancer Risk.Endocrine, metabolic & immune disorders drug targets · 2024Pooled it
- Dietary glycemic index, glycemic load and cancer risk: a meta-analysis of prospective cohort studies.European journal of nutrition · 2022Pooled it
- The Impact of Diabetes Mellitus on Renal Cell Carcinoma Prognosis: A Meta-Analysis of Cohort Studies.Medicine · 2015Pooled it
- Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2018Trial
- Sodium-glucose cotransporter 2 inhibitors and the risk of kidney cancer among patients with type 2 diabetes: a population-based cohort study.BMC medicine · 2026Article
- A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma.Oncology · 2025Article
- Plasma Proteomics of Type 2 Diabetes, Hypertension, and Co-Existing Diabetes/Hypertension in Thai Adults.Life (Basel, Switzerland) · 2024Article
- Transcriptomics analyses reveal the effects of Pentagamaboronon-0-ol on PI3K/Akt and cell cycle of HER2+ breast cancer cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Dietary glycemic index, glycemic load, and renal cancer risk: findings from prostate, lung, colorectal, and ovarian cancer trial.Frontiers in nutrition · 2023Article
- Versatile activity and morphological effects of zinc oxide submicron particles as anticancer agents.Nanomedicine (London, England) · 2022Article
- Trilateral association of autophagy, mTOR and Alzheimer's disease: Potential pathway in the development for Alzheimer's disease therapy.Frontiers in pharmacology · 2022Review
- Duration of diabetes mellitus and risk of kidney and bladder cancer: a longitudinal nationwide cohort study.American journal of cancer research · 2022Article
- Effects of HFrontiers in oncology · 2022Article
- TP63 Is Significantly Upregulated in Diabetic Kidney.International journal of molecular sciences · 2021Article
- The Role of Metabolic Factors in Renal Cancers.International journal of molecular sciences · 2020Review
- Article
- Obesity, DNA Damage, and Development of Obesity-Related Diseases.International journal of molecular sciences · 2019Review
- miR‑122 and miR‑199 synergistically promote autophagy in oral lichen planus by targeting the Akt/mTOR pathway.International journal of molecular medicine · 2019Article
- Galectin-1 is a new fibrosis protein in type 1 and type 2 diabetes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Advanced Glycation End Products Increase MDM2 Expression via Transcription Factor KLF5.Journal of diabetes research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recent study from our laboratory showed that patients with diabetes are at a higher risk of developing kidney cancer. In the current study, we have explored one of the mechanisms by which diabetes accelerates tumorigenesis in the kidney. Kidney cancer tissue from patients with diabetes showed a higher activity of Akt and decreased in total protein of tuberin compared to kidney cancer patient without diabetes or diabetes alone. In addition, a significant increase in phospho-Akt/tuberin expression was associated with an increase in Ki67 expression and activation of mTOR in kidney tumor with or without diabetes compared to diabetes alone. In addition, decrease in tuberin expression resulted in a significant decrease in protein expression of OGG1 and increased in oxidative DNA damage, 8-oxodG in kidney tissues from patients with cancer or cancer+diabetes. Importantly, these data showed that the majority of the staining of Akt/tuberin/p70S6K phosphorylation was more prominently in the tubular cells. In addition, accumulation of oxidative DNA damage is localized only in the nucleus of tubular cells within the cortex region. These data suggest that Akt/tuberin/mTOR pathway plays an important role in the regulation DNA damage and repair pathways that may predispose diabetic kidneys to pathogenesis of renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.